Cancers,
Journal Year:
2023,
Volume and Issue:
15(11), P. 3054 - 3054
Published: June 5, 2023
Acute
myeloid
leukemia
(AML)
is
a
devastating
disease.
Intensive
chemotherapy
the
mainstay
of
treatment
but
results
in
debilitating
toxicities.
Moreover,
many
treated
patients
will
eventually
require
hematopoietic
stem
cell
transplantation
(HSCT)
for
disease
control,
which
only
potentially
curative
challenging
option.
Ultimately,
subset
relapse
or
have
refractory
disease,
posing
huge
challenge
to
further
therapeutic
decisions.
Targeted
immunotherapies
hold
promise
relapsed/refractory
(r/r)
malignancies
by
directing
immune
system
against
cancer.
Chimeric
antigen
receptors
(CARs)
are
important
components
targeted
immunotherapy.
Indeed,
CAR-T
cells
achieved
unprecedented
success
r/r
CD19+
malignancies.
However,
modest
outcomes
clinical
studies
on
AML.
Natural
killer
(NK)
innate
anti-AML
functionality
and
can
be
engineered
with
CARs
improve
their
antitumor
response.
CAR-NKs
associated
lower
toxicities
than
cells;
however,
efficacy
AML
has
not
been
extensively
investigated.
In
this
review,
we
cite
from
describe
limitations
safety
concerns.
depict
preclinical
landscape
CAR
used
alternative
platforms
specific
focus
CAR-NKs,
providing
insight
into
future
optimization
Cell Proliferation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 27, 2024
The
recent
advancements
in
cancer
immunotherapy
have
spotlighted
the
potential
of
natural
killer
(NK)
cells,
particularly
chimeric
antigen
receptor
(CAR)-transduced
NK
cells.
These
pivotal
innate
immunity,
offer
a
rapid
and
potent
response
against
cells
pathogens
without
need
for
prior
sensitization
or
recognition
peptide
antigens.
Although
cell
genetic
modification
is
evolving,
viral
transduction
method
continues
to
be
inefficient
fraught
with
risks,
often
resulting
cytotoxic
outcomes
possibility
insertional
mutagenesis.
Consequently,
there
has
been
surge
development
non-viral
transfection
technologies
overcome
these
challenges
engineering.
Non-viral
approaches
CAR-NK
generation
are
becoming
increasingly
essential.
Cutting-edge
techniques
such
as
trogocytosis,
electroporation,
lipid
nanoparticle
(LNP)
delivery,
clustered
regularly
interspaced
short
palindromic
repeats-associated
protein
9
(CRISPR-Cas9)
gene
editing
transposons
not
only
enhance
efficiency
safety
engineering
but
also
open
new
avenues
novel
therapeutic
possibilities.
Additionally,
infusion
already
successful
CAR
T-cell
therapy
into
paradigm
holds
immense
further
advancements.
In
this
review,
we
present
an
overview
immunotherapies,
well
Cell & Bioscience,
Journal Year:
2023,
Volume and Issue:
13(1)
Published: March 9, 2023
Abstract
Background
NK
cell
is
one
of
innate
immune
cells
and
can
protect
the
body
from
cancer-initiating
cells.
It
has
been
reported
that
GPR116
receptor
involved
in
inflammation
tumors.
However,
effect
on
remains
largely
unclear.
Results
We
discovered
−/−
mice
could
efficiently
eliminate
pancreatic
cancer
through
enhancing
proportion
function
tumor.
Moreover,
expression
was
decreased
upon
activation
Besides,
showed
higher
cytotoxicity
antitumor
activity
vitro
vivo
by
producing
more
GzmB
IFNγ
than
wild-type
(WT)
Mechanistically,
regulated
via
Gαq/HIF1α/NF-κB
signaling
pathway.
Furthermore,
downregulation
promoted
NKG2D-CAR-NK92
against
both
vivo.
Conclusions
Our
data
indicated
had
a
negatively
enhance
activity,
which
provides
new
idea
to
efficiency
CAR
therapy.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(9), P. 8324 - 8324
Published: May 5, 2023
Malignant
bone
tumors
are
aggressive
tumors,
with
a
high
tendency
to
metastasize,
that
observed
most
frequently
in
adolescents
during
rapid
growth
spurts.
Pediatric
patients
malignant
sarcomas,
Ewing
sarcoma
and
osteosarcoma,
who
present
progressive
disease
have
dire
survival
rates
despite
therapy.
These
therapies
can
long-term
effects
on
growth,
such
as
decreased
mineral
density
reduced
longitudinal
growth.
New
therapeutic
approaches
therefore
urgently
needed
for
targeting
pediatric
tumors.
Harnessing
the
power
of
immune
system
against
cancer
has
improved
dramatically
certain
types.
Natural
killer
(NK)
cells
heterogeneous
group
innate
effector
possess
numerous
antitumor
effects,
cytolysis
cytokine
production.
been
shown
be
especially
susceptible
NK-cell-mediated
killing.
NK-cell
adoptive
therapy
confers
advantages
over
T-cell
therapy,
including
good
safety
profile
lack
major
histocompatibility
complex
restriction.
immunotherapy
potential
new
In
this
manuscript,
we
review
general
characteristics
osteosarcoma
sarcoma,
discuss
treatment
bones,
barriers
effective
sarcomas.
We
then
laboratory
clinical
studies
various
donor
sources
types,
engineering
NK
combinatorial
being
studied
overcome
current
challenges
while
suggesting
future
Cancers,
Journal Year:
2023,
Volume and Issue:
15(11), P. 3054 - 3054
Published: June 5, 2023
Acute
myeloid
leukemia
(AML)
is
a
devastating
disease.
Intensive
chemotherapy
the
mainstay
of
treatment
but
results
in
debilitating
toxicities.
Moreover,
many
treated
patients
will
eventually
require
hematopoietic
stem
cell
transplantation
(HSCT)
for
disease
control,
which
only
potentially
curative
challenging
option.
Ultimately,
subset
relapse
or
have
refractory
disease,
posing
huge
challenge
to
further
therapeutic
decisions.
Targeted
immunotherapies
hold
promise
relapsed/refractory
(r/r)
malignancies
by
directing
immune
system
against
cancer.
Chimeric
antigen
receptors
(CARs)
are
important
components
targeted
immunotherapy.
Indeed,
CAR-T
cells
achieved
unprecedented
success
r/r
CD19+
malignancies.
However,
modest
outcomes
clinical
studies
on
AML.
Natural
killer
(NK)
innate
anti-AML
functionality
and
can
be
engineered
with
CARs
improve
their
antitumor
response.
CAR-NKs
associated
lower
toxicities
than
cells;
however,
efficacy
AML
has
not
been
extensively
investigated.
In
this
review,
we
cite
from
describe
limitations
safety
concerns.
depict
preclinical
landscape
CAR
used
alternative
platforms
specific
focus
CAR-NKs,
providing
insight
into
future
optimization
